%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%% Introducci√≥n
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

@article{Pizzo2019,
abstract = {The association between fever and neutropenia and the risk for life-threatening infections in patients receiving cytotoxic chemo-therapy has been known for 50 years. Indeed, infectious complications have been a leading cause of morbidity and mortality in patients with cancer. This review chronicles the progress in defining and developing approaches to the management of fever and neutropenia through observational and controlled clinical trials done by single institutions, as well as by national and international collaborative groups. The resultant data have led to recommendations and guidelines from professional societies and frame the current principles of management. Recommendations include those guiding new treatment options (from mono-therapy to oral antibiotic therapy) and use of prophylactic anti-microbial regimens in high-risk patients. Of note, risk factors have changed with the advent of hematopoietic cytokines (espe-cially granulocyte colony-stimulating factor) in shortening the duration of neutropenia, as well as with the discovery of more targeted cancer treatments that do not result in cytotoxicity, although these are still the exception. Most guiding principles that were developed decades ago-about when to begin empirical treatment after a neutropenic patient becomes febrile, whether and how to modify the initial treatment regimen (espe-cially in patients with protracted neutropenia), and how long to continue antimicrobial therapy-are still used today. This review describes how the treatment principles related to the management of fever and neutropenia have responded to changes in the patients at risk, the microbes responsible, and the tools for their treatment, while still being sustained over the arc of time.},
author = {Pizzo, Philip A.},
doi = {10.7326/M18-3192},
file = {:C\:/Users/Daniel/OneDrive/Documents/Mendeley Desktop/Annals of Internal Medicine/2019/Annals of Internal Medicine - Management of patients with fever and neutropenia through the iarc of timei - Pizzo - 2019.pdf:pdf},
issn = {15393704},
journal = {Annals of Internal Medicine},
mendeley-groups = {NFPQ/JUSTIFICACION},
number = {6},
pages = {389--397},
title = {{Management of patients with fever and neutropenia through the arc of time}},
volume = {170},
year = {2019}
}


@article{Roberts2011,
abstract = {Infections in critically ill patients continue to result in unacceptably high morbidity and mortality. Although few data exist for correlating antibiotic exposure with outcome, antibiotic dosing is likely to be highly important for maximizing resolution of infection in many patients. The practical and financial difficulties of performing pharmacokinetic (PK) studies in critically ill patients mean that analyses to maximize data such as Monte Carlo simulation (MCS) are highly valuable. MCS uses computer software to perform virtual clinical trials. The building blocks for MCS are: firstly, a robust population PK model from the patient population of interest; secondly, descriptors of the effect of covariates that influence the PK parameters; thirdly, description of the susceptibility of bacteria to the antibiotic and finally a PK/pharmacodynamic (PD) target associated with antibiotic efficacy. Probability of target attainment (PTA) outputs can then be generated that describe the proportion of patients that will achieve a pre-specified PD target for an MIC distribution. Such analyses can then inform dosing requirements, which can be used to have a high likelihood of achieving PK/PD targets for organisms with different MICs. In this issue of JAC, Zelenitsky et al. provide a very useful example of MCS for interpreting the optimal methods for dosing meropenem, piperacillin/tazobactam, cefepime and ceftobiprole in critically ill patients. {\textcopyright} The Author 2010. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.},
author = {Roberts, Jason A. and Kirkpatrick, Carl M J and Lipman, Jeffrey},
doi = {10.1093/jac/dkq449},
file = {:C\:/Users/Daniel/OneDrive/Documents/Mendeley Desktop/Journal of Antimicrobial Chemotherapy/2011/Journal of Antimicrobial Chemotherapy - Monte Carlo simulations Maximizing antibiotic pharmacokinetic data to optimize clinical practice.pdf:pdf},
issn = {03057453},
journal = {Journal of Antimicrobial Chemotherapy},
keywords = {Dosing,Minimum inhibitory concentration,Pharmacodynamics,Population pharmacokinetics,Susceptibility},
mendeley-groups = {NFPQ/CAPITULO_1/NONMEM},
number = {2},
pages = {227--231},
title = {{Monte Carlo simulations: Maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients}},
volume = {66},
year = {2011}
}
@incollection{Zembower2014,
abstract = {Although major advances in the care of cancer patients over the past several decades have resulted in improved survival, infectious complications remain a significant cause of morbidity and mortality. To successfully identify, treat, and prevent infections, a comprehensive understanding of risk factors that predispose to infection and of commonly encountered pathogens is necessary. In addition, clinicians must keep abreast of the changing epidemiology of infections in this population. As therapeutic modalities continue to evolve, as established pathogens become increasingly drug resistant, and as new pathogens are discovered, successful management of infections will continue to present challenges in the years to come.},
address = {Chicago, USA},
author = {Zembower, Teresa R},
booktitle = {Infectious Complications in Cancer Patients},
doi = {10.1007/978-3-319-04220-6},
edition = {1},
file = {:C\:/Users/Daniel/OneDrive/Documents/Mendeley Desktop/Infectious Complications in Cancer Patients/2014/Infectious Complications in Cancer Patients - Epidemiology of Infections in Cancer Patients - Zembower - 2014.pdf:pdf},
isbn = {978-3-319-04219-0},
keywords = {Cancer,Emerging Pathogens,Epidemiology,Infection,Risk Factors},
mendeley-groups = {NFPQ/CAPITULO_1},
mendeley-tags = {Cancer,Emerging Pathogens,Epidemiology,Infection,Risk Factors},
publisher = {Springer US},
title = {{Epidemiology of Infections in Cancer Patients}},
volume = {161},
year = {2014}
}
@incollection{Castagnola2014,
abstract = {Principles and Practice of Infectious Diseases, Seventh Edition (2010) 3793-3807. doi:10.1016/B978-0-443-06839-3.00309-X},
address = {Maryland, USA},
author = {Castagnola, Elio and Mikulska, Magorzata and Viscoli, Claudio},
booktitle = {Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases},
doi = {10.1016/B978-1-4557-4801-3.00310-6},
edition = {7th},
editor = {Bennet, John E and Blasser, Martin J and Dolin, Raphael},
file = {:C\:/Users/Daniel/OneDrive/Documents/Mendeley Desktop/Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases/2014/Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases - Prophylaxis and Empirical Therapy.pdf:pdf},
isbn = {9996096742},
keywords = {Antimicrobial stewardship,Biologic response modifiers,Deescalation strategy,Empirical therapy,Febrile neutropenia,Fluoroquinolone prophylaxis,Immunocompromised,Invasive fungal disease,Leukemia,Multidrug-resistant (MDR) bacteria},
mendeley-groups = {NFPQ/CAPITULO_1},
pages = {3395--3413},
publisher = {Elsevier Inc.},
title = {{Prophylaxis and Empirical Therapy of Infection in Cancer Patients}},
volume = {2},
year = {2014}
}
@article{Cuervo-Maldonado2014,
abstract = {ObjetivosEl tratamiento actual de las neoplasias busca mejorar la sobrevivencia mediante la aplicaci{\'{o}}n de esquemas de quimioterapia intensificada, que produce una neutropenia m{\'{a}}s profunda y duradera, que favorece el desarrollo de infecciones bacterianas y mic{\'{o}}ticas invasoras. Este art{\'{i}}culo resume las recomendaciones de una gu{\'{i}}a para el diagn{\'{o}}stico y tratamiento de las infecciones bacterianas y mic{\'{o}}ticas en pacientes oncol{\'{o}}gicos mayores de 15 a{\~{n}}os con neutropenia febril posquimioterapia de alto riesgo. M{\'{e}}todosGu{\'{i}}a de pr{\'{a}}ctica cl{\'{i}}nica basada en la evidencia. Se realiz{\'{o}} la definici{\'{o}}n de preguntas cl{\'{i}}nicas, la b{\'{u}}squeda sistem{\'{a}}tica de literatura, la evaluaci{\'{o}}n cr{\'{i}}tica de la evidencia y la formulaci{\'{o}}n de recomendaciones. Se desarroll{\'{o}} una evaluaci{\'{o}}n econ{\'{o}}mica sobre la eficiencia de dos esquemas diferentes de tratamiento antimic{\'{o}}tico. ResultadosEl presente documento incluye recomendaciones para el diagn{\'{o}}stico de infecciones bacterianas y mic{\'{o}}ticas en paciente con neutropenia, el uso de profilaxis antibi{\'{o}}tica y antimic{\'{o}}tica, el tratamiento antibi{\'{o}}tico emp{\'{i}}rico, y el tratamiento antimic{\'{o}}tico emp{\'{i}}rico y anticipado en pacientes mayores de 15 a{\~{n}}os, acorde con la microbiolog{\'{i}}a del contexto colombiano. ConclusionesLa implementaci{\'{o}}n oportuna de las recomendaciones de la gu{\'{i}}a acorde con el contexto cl{\'{i}}nico de cada paciente debe contribuir a mejorar la supervivencia y morbilidad infecciosa de los pacientes con neutropenia febril derivada de la quimioterapia. ER },
author = {Cuervo-Maldonado, Sonia Isabel and Berm{\'{u}}dez, Carlos Daniel and Enciso, Leonardo and G{\'{o}}mez-Rinc{\'{o}}n, Julio C{\'{e}}sar and Castillo, Juan Sebasti{\'{a}}n and S{\'{a}}nchez, Ricardo and Ballesteros, M{\'{o}}nica Patricia and Buitrago, Giancarlo and Gamboa, {\'{O}}scar Andr{\'{e}}s and Acosta, Surella and Rivas-Pinedo, Pilar and Quevedo, Ruth and Arroyo, Claudia Patricia and D{\'{i}}az, Jorge Augusto},
doi = {10.1016/j.rccan.2014.06.002},
file = {:C\:/Users/Daniel/OneDrive/Documents/Mendeley Desktop/Revista Colombiana de Cancerolog{\'{i}}a/2014/Revista Colombiana de Cancerolog{\'{i}}a - Gu{\'{i}}a de pr{\'{a}}ctica cl{\'{i}}nica para el diagn{\'{o}}stico y el tratamiento de las infecciones bacterianas y mic{\'{o}}.pdf:pdf},
issn = {01239015},
journal = {Revista Colombiana de Cancerolog{\'{i}}a},
mendeley-groups = {NFPQ/Articulo_1},
number = {4},
pages = {186--196},
title = {{Gu{\'{i}}a de pr{\'{a}}ctica cl{\'{i}}nica para el diagn{\'{o}}stico y el tratamiento de las infecciones bacterianas y mic{\'{o}}ticas en pacientes oncol{\'{o}}gicos mayores de 15 a{\~{n}}os con neutropenia febril posquimioterapia de alto riesgo}},
volume = {18},
year = {2014}
}
@article{Nesher2014,
abstract = {Despite advancements in the treatment and supportive care of patients with malignant disorders, neutropenia remains the major side effect of most antineoplastic regimens. Infections occur frequently in neutropenic patients and are associated with considerable morbidity and mortality. The spectrum of infection continues to change, and is influenced by various factors including local epidemiology, the use of chemoprophylaxis, and the use of central venous catheters and other medical devices. Bacterial infections are common in the early stages of neutropenia, with fungal infections emerging if neutropenia persists beyond 7-10 days. Gram-positive organisms cause most bacteremic infections (although this trend appears to be changing), whereas infections at other sites are often caused by Gram-negative bacilli or are polymicrobial, especially if deep tissue infection is present. Candida spp., and Aspergillus spp., remain the most common fungal pathogens, although several opportunistic fungi have emerged. Resistance to antimicrobial and antifungal agents commonly used for the prevention and treatment of infections in neutropenic patients has become a significant problem. The prompt administration of appropriate, empiric, antimicrobial therapy, prior to the availability of microbiological culture results, is the standard of care. Up to date knowledge of the spectrum of infection and local susceptibility/resistance patterns, is critical. In this report, we describe the current spectrum of infection in patients with malignancies and neutropenia, and emphasize the fact that local and geographic differences are not infrequent. We recommend that individual institutions conduct periodic epidemiological surveys in order to have the latest data available for the optimal management of their patients.},
author = {Nesher, Lior and Rolston, Kenneth V I},
doi = {10.1007/s15010-013-0525-9},
file = {:C\:/Users/Daniel/OneDrive/Documents/Mendeley Desktop/Infection/2014/Infection - The current spectrum of infection in cancer patients with chemotherapy related neutropenia - Nesher, Rolston - 2014.pdf:pdf},
isbn = {1501001305259},
issn = {14390973},
journal = {Infection},
keywords = {Chemotherapy,Infection,Malignancy,Neutropenia},
mendeley-groups = {NFPQ/CAPITULO_1},
number = {1},
pages = {5--13},
title = {{The current spectrum of infection in cancer patients with chemotherapy related neutropenia}},
volume = {42},
year = {2014}
}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
@article{Ramos2012,
abstract = {Introducci{\'{o}}n: Los pacientes con neutropenia febril (NF) constituyen una poblaci{\'{o}}n heterog{\'{e}}nea que presenta un riesgo variable para el desarrollo de complicaciones, incluyendo la muerte. Objetivo: Describir las caracter{\'{i}}sticas cl{\'{i}}nicas y los diversos desenlaces en una cohorte de pacientes con NF, as{\'{i}} como las variables que influyeron sobre la mortalidad. Materiales y M{\'{e}}todos: Se realiz{\'{o}} un estudio ambidireccional que incluy{\'{o}} la informaci{\'{o}}n de 270 pacientes y 412 episodios de NF, recolectados en el per{\'{i}}odo comprendido entre el 1¬∞ de mayo del 2001 y el 31 marzo del 2008, en el Instituto Nacional de Cancerolog{\'{i}}a (INC). Todos los pacientes ten{\'{i}}an una neoplasia confirmada, m{\'{a}}s de 18 a{\~{n}}os de edad y el diagn{\'{o}}stico de NF. Se evaluaron m{\'{u}}ltiples variables demogr{\'{a}}ficas, microbiol{\'{o}}gicas y cl{\'{i}}nicas, referentes al tratamiento y al desenlace final de los pacientes. Se practic{\'{o}} el an{\'{a}}lisis univariado y multivariado de las variables que modificaron la supervivencia global. Resultados: El promedio de edad de los pacientes incluidos fue de 41.6 a{\~{n}}os; la incidencia de bacteremia fue del 26.5%, siendo el hallazgo microbiol{\'{o}}gico m{\'{a}}s frecuente en los hemocultivos el de los g{\'{e}}rmenes Gram negativos. La tasa de mortalidad por NF fue de 7.3 por 100.000 pacientes d{\'{i}}a y en el an{\'{a}}lisis univariado las variables que se asociaron de forma significativa con la mortalidad fueron: el estado mental (HR 13.34, IC95% 6.34-32.82), la hipotensi{\'{o}}n (HR 5.4, IC95% 2.77-10.83), la falla renal (HR 5.40, IC95% 2.40-12.12), la deshidrataci{\'{o}}n (HR 6.67, IC95% 3.40-13.08), la falla respiratoria (HR 9.82, IC95% 8.48-20.01) y la fungemia (HR 4.88, IC95% 1.46-16.30). Los an{\'{a}}lisis univariado y multivariado descartaron que la bacteremia se hubiera asociado con la mortalidad. En el an{\'{a}}lisis multivariado la mortalidad solo se modific{\'{o}} por la falla respiratoria (HR 4.23, IC95% 1.87-9.59) ante la alteraci{\'{o}}n del estado mental (HR 3.96, IC95% 1.61-9.75) y por la deshidrataci{\'{o}}n (HR 2.49, IC95% 1.10-5.65). Conclusi{\'{o}}n: La tasa de mortalidad por NF fue comparable con lo reportado previamente por la literatura m{\'{e}}dica. La bacteremia no modific{\'{o}} la mortalidad, pero s{\'{i}} otros factores que podr{\'{i}}an ayudar a identificar pacientes de alto riesgo.},
author = {Ramos, Pedro and S{\'{a}}nchez, Ricardo and Gamboa, {\'{O}}scar and Cardona, Andr{\'{e}}s Felipe},
file = {:C\:/Users/Daniel/OneDrive/Documents/Mendeley Desktop/Revista Colombiana de Hematolog{\'{i}}a y Oncolog{\'{i}}a/2012/Revista Colombiana de Hematolog{\'{i}}a y Oncolog{\'{i}}a - Factores pron{\'{o}}sticos relacionados con la mortalidad en pacientes con c{\'{a}}ncer y neutropeni.pdf:pdf},
journal = {Revista Colombiana de Hematolog{\'{i}}a y Oncolog{\'{i}}a},
keywords = {bacteremia,factores de riesgo,fiebre,neutropenia,pron{\'{o}}stico},
mendeley-groups = {NFPQ/CAPITULO_1/Colombia},
number = {4},
pages = {15--22},
title = {{Factores pron{\'{o}}sticos relacionados con la mortalidad en pacientes con c{\'{a}}ncer y neutropenia febril}},
volume = {1},
year = {2012}
}
@article{CortesJA2013,
author = {{Cortes JA} and {Cuervo S} and {Gomez CA} and {Bermudez D} and {Martinez T} and {Arroyo P.}},
journal = {Biomedica},
mendeley-groups = {NFPQ/CAPITULO_1},
number = {1},
pages = {70--77},
title = {{Febrile neutropenia in the tropics: a description of clinical and microbiological findings and their impact on inappropriate therapy currently used at an oncological reference center in Colombia.}},
volume = {33},
year = {2013}
}
@article{Madrid2013,
abstract = {Febrile neutropenia (FN) is a significant adverse effect post-chemotherapy due to its high morbidity and mortality. There are few studies in our country with these kind of patients. To describe the characteristics and mortality in patients with hematologic neoplasms who developed FN post-chemotherapy. A descriptive case series in patients with hematologic neoplasms who developed FN post-chemotherapy in Hospital Pablo Tob?n Uribe. 101 episodes of FN in 43 patients. The median age was 44 years. 63.5% of patients had no apparent clinical focus of infection at admission, 11.8% had soft tissue compromise and 8.9% urinary tract infection. Bacteremia was documented in 41.5% and catheter-associated bacteremia in 3.9%. The most common organisms were Escherichia coli 43.4%, Klebsiella pneumoniae 17.3% and Staphylococcus aureus 8.6%. Of those isolated in blood 84.7% were Gram negative rods and 15.2% were Gram positive bacteria. Piperacillin/tazobactam was the most common empirically prescribed antibiotic (81.1%). Mortality of FN episodes occurred in 8 (7.92%) patients, 5 (62.5%) attributable to infection and 3 (37.5%) due to progression of hematologic malignancy with a resolution of FN. In our case series of FN the microbiological characteristics differed significantly from developed countries, but a similar mortality rate per episode was observed.},
author = {Madrid, Camilo and D{\'{i}}az, Laura and Combariza, Juan and G{\'{a}}lvez, Kenny and Olaya, Viviana and Ram{\'{i}}rez, Isabel and Donado, Jorge},
doi = {10.4067/s0716-10182013000200010},
file = {:C\:/Users/Daniel/OneDrive/Documents/Mendeley Desktop/Revista chilena de infectolog{\'{i}}a/2013/Revista chilena de infectolog{\'{i}}a - Epidemiolog{\'{i}}a de la neutropenia febril en pacientes adultos con neoplasia hematol{\'{o}}gica, en un per{\'{i}}odo.pdf:pdf},
issn = {0716-1018},
journal = {Revista chilena de infectolog{\'{i}}a},
keywords = {bacteremia,bacteriemia,bolivariana,colombia,fever,fiebre,hematologic neoplasms,medell{\'{i}}n,neoplasias hematol{\'{o}}gicas,neutropenia,palabras clave,universidad pontificia},
mendeley-groups = {NFPQ/CAPITULO_1/Colombia},
number = {2},
pages = {195--201},
title = {{Epidemiolog{\'{i}}a de la neutropenia febril en pacientes adultos con neoplasia hematol{\'{o}}gica, en un per{\'{i}}odo de 26 meses en el Hospital Pablo Tob{\'{o}}n Uribe, Colombia}},
volume = {30},
year = {2013}
}
@article{PalacioMesa2015,
author = {{Palacio Mesa}, Mar{\'{i}}a Juliana and {Diosa Restrepo}, Mariana and Ram{\'{i}}rez-Pulgar{\'{i}}n, Sergio and Mart{\'{i}}nez-S{\'{a}}nchez, Lina Maria and {Rodr{\'{i}}guez G{\'{a}}zquez}, Maria de los {\'{A}}ngeles and {Orozco Forero}, Juan Pablo},
file = {:C\:/Users/Daniel/OneDrive/Documents/Mendeley Desktop/Archivos de Medicina (Col)/2015/Archivos de Medicina (Col) - Perfil cl{\'{i}}nico y microbiol{\'{o}}gico de ni{\~{n}}os con neutropenia febril posterior a tratamientos antineopl{\'{a}}sicos tr.pdf:pdf},
journal = {Archivos de Medicina (Col)},
keywords = {Neutropenia febril, morbilidad, antineopl{\'{a}}sicos.,antineopl{\'{a}}sicos.,morbilidad},
mendeley-groups = {NFPQ/CAPITULO_1/Colombia},
number = {1},
pages = {25--32},
title = {{Perfil cl{\'{i}}nico y microbiol{\'{o}}gico de ni{\~{n}}os con neutropenia febril posterior a tratamientos antineopl{\'{a}}sicos tratados en una instituci{\'{o}}n hospitalaria de Medell{\'{i}}n (Colombia), 2009-2010: Estudio de serie de casos}},
volume = {15},
year = {2015}
}
@phdthesis{BermudezSilva2009,
abstract = {Descripci{\'{o}}n: se estudia la poblaci{\'{o}}n de pacientes atendidos en el Instituto Nacional de Cancerolog{\'{i}}a con diagn{\'{o}}stico de leucemia linfoide aguda, atendidos en el 2008 con el fin de establecer factores de riesgo y describir las caracter{\'{i}}sticas generales de la neutropenia febril. Resultados: de los 112 eventos documentados se present{\'{o}} neutropenia febril en 66%, con un promedio de edad de 29.8 a{\~{n}}os, y predominio femenino. En este grupo un 78.38% se clasificaron como grupo alto riesgo y 21.62 % en riesgo est{\'{a}}ndar. Las quimioterapias m{\'{a}}s implicadas son: HyperCVAD par, HyperCVAD impar y la totalidad de los pacientes manejados con el esquema IDA-FLAG. El promedio de neutropenia fue de 11.62 d{\'{i}}as; con un tiempo de aparici{\'{o}}n de 8.26 d{\'{i}}as. En 1/3 de los pacientes se logra aislamiento microbiol{\'{o}}gico, siendo m{\'{a}}s frecuente K. pneumoniae; seguido de E. coli; y S. epidermidis; en el grupo de neutropenia prolongada hay mayor porcentaje de cambio de antibi{\'{o}}tico, as{\'{i}} mismo como el uso de vancomicina (76.9%), anfotericina (89.4%) y voriconazol (87.5%). Encontramos asociaci{\'{o}}n estad{\'{i}}sticamente significativa entre la aparici{\'{o}}n de neutropenia febril y la categor{\'{i}}a de alto riesgo, mostrando un OR de 3.682 con IC: 1.403?9.662 con un valor de p=0.008. La mortalidad por neutropenia febril en nuestra instituci{\'{o}}n fue de 11.6%. Siendo baja para los est{\'{a}}ndares internacionales},
author = {{Berm{\'{u}}dez Silva}, Carlos Daniel},
file = {:C\:/Users/Daniel/OneDrive/Documents/Mendeley Desktop/Unknown/2009/Unknown - Caracterizaci{\'{o}}n de la neutropenia febril en pacientes con leucemia linfoide aguda, tratados con quimioterapia de alto riesgo,.pdf:pdf},
keywords = {ARRAY(0x7f65fd4825f8)},
mendeley-groups = {NFPQ/CAPITULO_1/Colombia},
pages = {101},
school = {Universidad Nacional de Colombia},
title = {{Caracterizaci{\'{o}}n de la neutropenia febril en pacientes con leucemia linfoide aguda, tratados con quimioterapia de alto riesgo, atendidos en el Instituto Nacional de Cancerolog{\'{i}}a desde 1 de enero al 31 de diciembre de 2008}},
type = {Tesis de Especialidad},
url = {http://www.bdigital.unal.edu.co/2447/},
year = {2009}
}
@phdthesis{ToscanoRodriguez2015,
author = {{Toscano Rodr{\'{i}}guez}, Silvia Mar{\'{i}}a and {Galindo {\'{A}}ngel}, Andr{\'{e}}s Felipe},
file = {:C\:/Users/Daniel/OneDrive/Documents/Mendeley Desktop/Unknown/2015/Unknown - Caracterizaci{\'{o}}n de los eventos de neutropenia febril en ni{\~{n}}os con cancer - Toscano Rodr{\'{i}}guez, Galindo {\'{A}}ngel - 2015.pdf:pdf},
mendeley-groups = {NFPQ/CAPITULO_1/Colombia},
pages = {1--62},
school = {Universidad del Rosario},
title = {{Caracterizaci{\'{o}}n de los eventos de neutropenia febril en ni{\~{n}}os con cancer}},
type = {Tesis de Especialidad},
year = {2015}
}
@phdthesis{RinconFuerte2013,
author = {{Rinc{\'{o}}n Fuerte}, Carolina},
file = {:C\:/Users/Daniel/OneDrive/Documents/Mendeley Desktop/Unknown/2013/Unknown - Caracterizaci{\'{o}}n de episodios de neutropenia febril en ni{\~{n}}os con c{\'{a}}ncer en la Fundaci{\'{o}}n Hospital de la Misericordia - Rinc{\'{o}}n Fu.pdf:pdf},
mendeley-groups = {NFPQ/CAPITULO_1/Colombia},
school = {Departamento de Pediatr{\'{i}}a - Facultad de Medicina},
title = {{Caracterizaci{\'{o}}n de episodios de neutropenia febril en ni{\~{n}}os con c{\'{a}}ncer en la Fundaci{\'{o}}n Hospital de la Misericordia}},
type = {Tesis de Especialidad},
year = {2013}
}
@phdthesis{VizcainoGarcia2014,
abstract = {Introducci{\'{o}}n: Las infecciones en ni{\~{n}}os con c{\'{a}}ncer son una de las principales causas de morbimortalidad en este grupo de pacientes. En las {\'{u}}ltimas dos d{\'{e}}cadas, se han dise{\~{n}}ado escalas para categorizar el riesgo de Infecci{\'{o}}n Bacteriana Invasiva (IBI) en pacientes que consultan por neutropenia febril desde su ingreso. En Cartagena de Indias no existe una caracterizaci{\'{o}}n epidemiol{\'{o}}gica y cl{\'{i}}nica de estos individuos que consulta por neutropenia febril, y a{\'{u}}n menos una evaluaci{\'{o}}n del riesgo de IBI en ellos al consultar a urgencias. Objetivos: Caracterizar los episodios de neutropenias febriles en ni{\~{n}}os del Hospital Infantil Napole{\'{o}}n Franco Pareja (HINFP) y evaluar el desempe{\~{n}}o del modelo predictivo de IBI por Santolaya. M{\'{e}}todos: Fueron seleccionados ni{\~{n}}os con c{\'{a}}ncer que consultaban al servicio de urgencias del HINFP con neutropenia febril. Los datos fueron obtenidos a partir de las historias cl{\'{i}}nicas y fueron comparados entre los grupos con y sin IBI. La asociaci{\'{o}}n entre alguna con la presencia de IBI se realiz{\'{o}} mediante regresi{\'{o}}n log{\'{i}}stica. Adem{\'{a}}s, se determinaron las caracter{\'{i}}sticas operativas del modelo de Santolaya para predecir IBI. Resultados: Fueron registrados 61 episodios, en 35 individuos, de los cuales 21 presentaron IBI. La reca{\'{i}}da tumoral [OR 6,16 (1,39-27,24), p=0,016], la temperatura al ingreso [OR 0,45 (0,23-0,85), p=0,015], los hemoglobina menor a 9 gr/dL [OR 4,8 (1,5- 15,33), p=0,008], los niveles de leucocitos[OR 0,49 (0,27-0,89), p =0,09], la neutropenia severa [OR 8,82 (2,46-31,5), p=0,001] y la trombocitopenia [OR 3,38 (1,08-10,5), p=0,035] se asociaron con la presencia de IBI. La sensibilidad, especificidad, valor predictivo positivo y negativo del modelo predictivo de Santolaya fueron 66%, 60%, 53% y 77,4%, respectivamente. Conclusiones: Las reca{\'{i}}das tumorales y la trombocitopenia se confirman como factores de riesgo para IBI en este estudio. El modelo predictivo de Santolaya tuvo una regular eficiencia para predecir IBI. La hemoglobina podr{\'{i}}a ser un factor predictor de IBI en nuestra poblaci{\'{o}}n.},
author = {{Vizcaino Garcia}, Hugo Manuel},
file = {:C\:/Users/Daniel/OneDrive/Documents/Mendeley Desktop/Unknown/2014/Unknown - Caracterizaci{\'{o}}n cl{\'{i}}nica y epidemiol{\'{o}}gica de los pacientes pedi{\'{a}}tricos oncol{\'{o}}gicos con neutropenia febril - Vizcaino Garcia - 2.pdf:pdf},
mendeley-groups = {NFPQ/CAPITULO_1/Colombia},
pages = {1--24},
school = {Universidad de Cartagena},
title = {{Caracterizaci{\'{o}}n cl{\'{i}}nica y epidemiol{\'{o}}gica de los pacientes pedi{\'{a}}tricos oncol{\'{o}}gicos con neutropenia febril}},
type = {Tesis de Especialidad},
year = {2014}
}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%



%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%% Resultados
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
@phdthesis{JCAR2015,
author = {{{\'{A}}lvarez Rodr{\'{i}}guez}, Jos{\'{e}} Camilo and {Cuervo Maldonado}, Sonia Isabel and {Cort{\'{e}}s Luna}, Jorge Alberto and {S{\'{a}}nchez Pedraza}, Ricardo and {Silva G{\'{o}}mez}, Edelberto and D{\'{i}}az, Jorge Augusto and G{\'{o}}mez, Julio Cesar},
file = {:C\:/Users/Daniel/OneDrive/Documents/Mendeley Desktop/Unknown/2015/Unknown - Farmacocin{\'{e}}tica de Cefepime en pacientes con neoplasias hematol{\'{o}}gicas y neutropenia febril post-quimioterapia en el Instituto.pdf:pdf},
keywords = {Cefepime,Referencia Maestra},
mendeley-groups = {NFPQ/CAP{\'{I}}TULO_3},
pages = {1--73},
school = {Universidad Nacional de Colombia},
title = {{Farmacocin{\'{e}}tica de cefepime en pacientes con neoplasias hematol{\'{o}}gicas y neutropenia febril post-quimioterapia en el Instituto Nacional de Cancerolog{\'{i}}a, Empresa Social del Estado, Bogot{\'{a}}}},
type = {Tesis de Especialidad},
year = {2015}
}
@phdthesis{JAPM2016,
author = {{P{\'{e}}rez Mesa}, Jefferson Alejandro and {Cuervo Maldonado}, Sonia Isabel and {Cort{\'{e}}s Luna}, Jorge Alberto and {S{\'{a}}nchez Pedraza}, Ricardo and {Silva G{\'{o}}mez}, Edelberto and D{\'{i}}az, Jorge Augusto and {G{\'{o}}mez Rinc{\'{o}}n}, Julio Cesar and Enciso, Leonardo and Rodr{\'{i}}guez, Elizabeth},
file = {:C\:/Users/Daniel/OneDrive/Documents/Mendeley Desktop/Unknown/2016/Unknown - Farmacocin{\'{e}}tica de un producto de Vancomicina en pacientes con neoplasias hematol{\'{o}}gicas y neutropenia febril post-quimioterapi.pdf:pdf},
keywords = {Referencia Maestra,Vancomicina},
mendeley-groups = {NFPQ/CAP{\'{I}}TULO_3},
pages = {1--53},
school = {Universidad Nacional de Colombia},
title = {{Farmacocin{\'{e}}tica de un producto de Vancomicina en pacientes con neoplasias hematol{\'{o}}gicas y neutropenia febril post-quimioterapia en el Instituto Nacional de Cancerolog{\'{i}}a, Empresa Social del Estado, Bogot{\'{a}} ‚ÄìColombia}},
type = {Tesis de Especialidad},
year = {2016}
}

